Payment overview · 2025
General Payments
$456.54
24 reported records · 17 companies
Healthcare provider profile · identity verified
David Earl Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PADUCAH, KY · NPI 1912903741
Verified facts
What the public records show
CMS Open Payments records show David Earl Smith, M.D. received $456.54 in general payments during 2025 across 24 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.96 | 11.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.45 | 10.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $39.95 | 8.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.14 | 8.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.68 | 7.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.71 | 6.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.38 | 5.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.09 | 5.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.61 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.82 | 4.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $21.36 | 4.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.03 | 4.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.63 | 4.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.39 | 3.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $15.23 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.23 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.88 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $456.54 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.96 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.45 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.14 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 130 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 192 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 32 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
192 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 598 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 475 | 119 |
| Lisinopril | Lisinopril | 423 | 116 |
| Gabapentin | Gabapentin | 407 | 78 |
| Omeprazole | Omeprazole | 372 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 367 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 330 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 78 |
| Metformin Hcl | Metformin Hcl | 310 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 270 | 65 |
| Furosemide | Furosemide | 235 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 54 |
| Carvedilol | Carvedilol | 211 | 63 |
| Ozempic | Semaglutide | 192 | 35 |
| Losartan Potassium | Losartan Potassium | 190 | 51 |
| Meloxicam | Meloxicam | 187 | 49 |
| Montelukast Sodium | Montelukast Sodium | 170 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 160 | 57 |
| Sertraline Hcl | Sertraline Hcl | 159 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 157 | 43 |
| Metformin Hcl Er | Metformin Hcl | 157 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 154 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 33 |
| Lorazepam | Lorazepam | 145 | 23 |
| Trazodone Hcl | Trazodone Hcl | 140 | 31 |
| Famotidine | Famotidine | 138 | 33 |
| Jardiance | Empagliflozin | 130 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 114 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 28 |
| Ondansetron Odt | Ondansetron | 105 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 26 |
| Clonidine Hcl | Clonidine Hcl | 93 | 20 |
| Buspirone Hcl | Buspirone Hcl | 92 | 19 |
| Eliquis | Apixaban | 89 | 17 |
| Potassium Chloride | Potassium Chloride | 89 | 21 |
| Pregabalin | Pregabalin | 84 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 14 |
| Aripiprazole | Aripiprazole | 80 | 16 |
| Farxiga | Dapagliflozin Propanediol | 79 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 25 |
| Allopurinol | Allopurinol | 76 | 18 |
| Bupropion Xl | Bupropion Hcl | 75 | 17 |
| Spironolactone | Spironolactone | 74 | 22 |
| Alprazolam | Alprazolam | 73 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 19 |
| Meclizine Hcl | Meclizine Hcl | 72 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 71 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 18 |
| Fenofibrate | Fenofibrate,micronized | 67 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 13 |
| Januvia | Sitagliptin Phosphate | 61 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 11 |
| Prednisone | Prednisone | 58 | 41 |
| Bumetanide | Bumetanide | 56 | 19 |
| Ibuprofen | Ibuprofen | 54 | 15 |
| Promethazine Hcl | Promethazine Hcl | 54 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 53 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 12 |
| Glimepiride | Glimepiride | 52 | 16 |
| Simvastatin | Simvastatin | 52 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 51 | 20 |
| Diazepam | Diazepam | 50 | suppressed |
| Glipizide Er | Glipizide | 50 | 11 |
| Irbesartan | Irbesartan | 49 | 18 |
| Celecoxib | Celecoxib | 48 | 12 |
| Mirtazapine | Mirtazapine | 48 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 33 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 27 |
| Vraylar | Cariprazine Hcl | 39 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | 20 |
| Azelastine Hcl | Azelastine Hcl | 34 | 11 |
| Novolog Flexpen | Insulin Aspart | 34 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Nystatin | Nystatin | 32 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Prempro | Estrogen,con/M-Progest Acet | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Indomethacin Er | Indomethacin | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $456.54 · 24 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AIRSUPRA, Auvelity, COBENFY, COMIRNATY, Dexcom G6 Transmitter, ENTRESTO, FARXIGA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NUZYRA, Ozempic, PREVNAR 20, Rybelsus, SPRAVATO, TONMYA, VOQUEZNA, Veozah, XHANCE, ZENPEP, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error